Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 20

Outcome	Group	Category	Value	Spread	Units
Disease Free Survival	Arm 1: Adriamycin + Cyclophosphamide		80.1		percentage of participants
Disease Free Survival	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide		79.4		percentage of participants
Survival	Arm 1: Adriamycin + Cyclophosphamide		89.8		percentage of participants alive
Survival	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide		89.9		percentage of participants alive
Adverse Events	Arm 1: Adriamycin + Cyclophosphamide		28.5		percentage of participants
Adverse Events	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide		45.0		percentage of participants
Quality of Life-Functional Assessment of Cancer Therapy	Arm 1: Adriamycin + Cyclophosphamide	Score day 1 cycle 4	61.7	95% Confidence Interval 60.9 to 62.7	score on a scale
Quality of Life-Functional Assessment of Cancer Therapy	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide	Score day 1 cycle 4	60.3	95% Confidence Interval 59.4 to 61.2	score on a scale
Quality of Life-Functional Assessment of Cancer Therapy	Arm 1: Adriamycin + Cyclophosphamide	Score 6 months	69.2	95% Confidence Interval 68.3 to 70.1	score on a scale
Quality of Life-Functional Assessment of Cancer Therapy	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide	Score 6 months	66.9	95% Confidence Interval 66.0 to 67.8	score on a scale
Quality of Life-Functional Assessment of Cancer Therapy	Arm 1: Adriamycin + Cyclophosphamide	Score 12 months	71.7	95% Confidence Interval 70.8 to 72.7	score on a scale
Quality of Life-Functional Assessment of Cancer Therapy	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide	Score 12 months	71.1	95% Confidence Interval 70.2 to 72.0	score on a scale
Post Chemotherapy Amenorrhea	Arm 1: Adriamycin + Cyclophosphamide		59.1		percentage of participants
Post Chemotherapy Amenorrhea	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide		67.4		percentage of participants
Change in Left Ventricular Ejection Fraction (LVEF) at the 12-month Evaluation	Arm 1: Adriamycin + Cyclophosphamide		-2.61	95% Confidence Interval -3.70 to -1.53	Change in percent ejection fraction
Change in Left Ventricular Ejection Fraction (LVEF) at the 12-month Evaluation	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide		-2.65	95% Confidence Interval -3.79 to -1.52	Change in percent ejection fraction
Recurrence-free Interval	Arm 1: Adriamycin + Cyclophosphamide		10.8		percentage of participants
Recurrence-free Interval	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide		10.4		percentage of participants
Distant Recurrence-free Interval	Arm 1: Adriamycin + Cyclophosphamide		8.3		percentage of participants
Distant Recurrence-free Interval	Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide		7.2		percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00087178/results

API reference For AI assistants